Amneal Continues To See Value In Complexity
After A ‘Solid’ 2022, Amneal Wants To Deliver On Complex Generics And Biosimilars
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.
You may also be interested in...
Fresh Competition Coming For Narcan In US
Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.
Amneal Reveals Orion As European Partner
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.
Amneal Sets $200m Sales Ambition For Biosimilar Trio
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.